Director/PDMR Shareholding

RNS Number : 7498T
Oxford Biomedica PLC
22 November 2013

For immediate release

22 November 2013


Oxford BioMedica plc Director's Share Purchase


Oxford, UK - 22 November 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 22 November that one of its Directors has acquired ordinary shares of 1p each ("Ordinary Shares") as follows:






Interest after purchase

Director / PDMR


Price per share (p)

Number of Ordinary Shares acquired on

22 November 2013

Number of Ordinary Shares

% of total

issued share capital

Nick Rogers







The issued share capital of the Company is 1,416,149,005 1p ordinary shares.




For further information, please contact:


Oxford BioMedica plc:

Lara Mott, Head of Investor Relations and Corporate Communications


Tel: +44 (0)1865 783 000


Media/Financial Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications


Tel: +44 (0)20 7920 2354



Notes to editors


1. About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at and



This information is provided by RNS
The company news service from the London Stock Exchange